Patents Assigned to Amgen
-
Publication number: 20250147008Abstract: Method for investigating subcutaneous administration of a therapeutic compound product comprising providing a live in vitro mammalian skin sample comprising a dermal layer and epidermal layer, administering a therapeutic compound product to the interface between the dermal layer and the epidermal layer and analysing the skin sample.Type: ApplicationFiled: August 19, 2022Publication date: May 8, 2025Applicant: AMGEN INC.Inventors: Marisa K. JOUBERT, Nathan H. JOH, Joshua M. TOKUDA, John FERBAS, Jiansong XIE, Dong XIANG
-
Patent number: 12290666Abstract: Methods, devices, and components are provided to reduce tissue resistive pressure during a subcutaneous drug delivery operation by increasing the size of the injection cavity by partially retracting the drug delivery member after inserting the drug delivery member to a subcutaneous position. The drug delivery devices described herein include a resilient member that interacts between stationary and moveable components of the drug delivery device. The drug delivery device include drives to move the stationary and moveable components relative to one another to insert a drug delivery member to a subcutaneous depth within a patient and to dispense a drug to the injection cavity in the patient. The resilient member is deformed during the operations or is pre-deformed and the stored energy of the resilient member in the deformed state then acts on the stationary and moveable components to partially retract the drug delivery member to relieve pressure in the injection region.Type: GrantFiled: October 22, 2019Date of Patent: May 6, 2025Assignee: AMGEN INC.Inventors: Ali Nekouzadeh, Carl Conrath, Basel Hasan Taha
-
Publication number: 20250136667Abstract: Methods of isolating a therapeutic protein from a sample are described herein. Kits for isolating a therapeutic protein from a sample are described herein.Type: ApplicationFiled: August 5, 2022Publication date: May 1, 2025Applicant: Amgen Inc.Inventors: Qingchun ZHANG, Lidong HE, Mark KROENKE, Nicolas H. ANGELL, Suminda HAPUARACHCHI
-
Publication number: 20250129050Abstract: The present invention relates to improved preparation of a KIF18A inhibitor having the chemical structure Compound (1), or a salt thereof Compound (la); wherein HA is as defined herein; and key intermediates thereof, i.e., Compound (2a), Compound (3a), Compound (5) or a salt thereof, and Compound (6a) or a hydrate thereof, of the formulae: Compound (2a); Compound (3a); Compound (5) or a salt thereof; and Compound (6a) or a hydrate thereof, preferably Compound (6a-1). The present invention further relates to solid form of Compound (6a), preferably the crystalline hydrate form of Compound (6a-1).Type: ApplicationFiled: January 26, 2023Publication date: April 24, 2025Applicant: Amgen Inc.Inventors: Sebastien CAILLE, Daniel Gerard GREENE, Michael Thomas CORBETT, Carolyn WEI
-
Publication number: 20250129072Abstract: Provided herein is a process for preparing compound A comprising (a) admixing 2-isopropyl-4-methylpyridin-3-amine (Compound B), or a salt thereof, a first base, and a reactive compound comprising phosgene or a phosgene equivalent in an organic solvent to form 3-isocyanato-2-isopropyl-4-methylpyridine (Compound C); (b) admixing Compound C and 2,6-dichloro-5-fluoronicotinamide (Compound D) to form 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Compound E); and (c) admixing Compound E and a second base to form a product mixture comprising Compound A and the second base.Type: ApplicationFiled: December 19, 2024Publication date: April 24, 2025Applicant: AMGEN INC.Inventors: Michal ACHMATOWICZ, John T. COLYER, Michael T. CORBETT, Daniel J. GRIFFIN, Andrew T. PARSONS, Joanna ROBINSON, Kyle QUASDORF
-
Publication number: 20250129160Abstract: The present invention provides single chain T cell engager (TCE) molecules having an scFab that binds a target antigen and an scFv that binds CD3, and TCE molecules that bind CCR8 and CD3. Methods of treating cancer are also provided.Type: ApplicationFiled: June 2, 2022Publication date: April 24, 2025Applicants: AMGEN RESEARCH (MUNICH) GmbH, AMGEN INC.Inventors: Johannes BROZY, Christoph DAHLHOFF, Tobias RAUM, Jochen S. PENDZIALEK, Lisa WINKEL, Marcus MUENZ, Nathan William PIERCE, Agnieszka KIELCZEWSKA, Wentao CHEN, Darren L. BATES, Claudia BLUEMEL, Jonas Karl-Josef HONER
-
Publication number: 20250129172Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: ApplicationFiled: October 2, 2024Publication date: April 24, 2025Applicant: AMGEN INC.Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
-
Patent number: 12281176Abstract: The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: GrantFiled: June 1, 2021Date of Patent: April 22, 2025Assignees: Amgen Inc., Amgen Research (Munich) GmbHInventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
-
Patent number: 12281175Abstract: The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: GrantFiled: September 3, 2020Date of Patent: April 22, 2025Assignees: Amgen Inc., Amgen Research (Munich) GmbHInventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
-
Patent number: 12281172Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.Type: GrantFiled: April 2, 2021Date of Patent: April 22, 2025Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Doris Rau, Susanne Mangold, Matthias Klinger, Evelyne Schaller, Susanne Hausmann, Petra Fluhr, Carola Steiger
-
Patent number: 12280056Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.Type: GrantFiled: December 19, 2023Date of Patent: April 22, 2025Assignee: Amgen Inc.Inventors: James Russell Lipford, Jude Robert Canon, Anne Y. Saiki, Karen Louise Rex
-
Publication number: 20250122494Abstract: Provided herein are methods of separating molecular species of a guanine-rich oligonucleotide from a mixture of molecular species, wherein at least one molecular species of the mixture is a quadruplex formed from the guanine-rich oligonucleotide. In exemplary embodiments, the methods comprise (a) applying the mixture to a chromatographic matrix comprising a hydrophobic ligand, wherein said hydrophobic ligand comprises C4 to C8 alkyl chains, wherein molecular species bind to the hydrophobic ligand and (b) applying a mobile phase which comprises a gradient of acetate and a gradient of acetonitrile but no cationic ion pairing agent to the chromatographic matrix to elute molecular species of the guanine-rich oligonucleotide. In exemplary aspects, the guamne-rich oligonucleotide elutes in a first set of elution fractions and a quadruplex formed from the guanine-rich oligonucleotide elutes in a second set of elution fractions.Type: ApplicationFiled: September 29, 2022Publication date: April 17, 2025Applicant: AMGEN INC.Inventors: Robert J. DUFF, Helena SCHILLINGER, Jennifer LIPPENS
-
Publication number: 20250122222Abstract: The present disclosure provides compounds useful for the inhibition of KRAS. The compounds have a general Formula I: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.Type: ApplicationFiled: August 10, 2022Publication date: April 17, 2025Applicant: AMGEN INC.Inventors: Michael M. YAMANO, Yunxiao LI, Primali Vasundera NAVARATNE, Jose M. MEDINA, Ning CHEN, Liping PETTUS, Rene RAHIMOFF, Xiaofen LI, John STELLWAGEN, Francesco MANONI, Kexue LI, Brian Alan LANMAN, Ryan Paul Wurz, Wei ZHAO, Huan RUI, Josephine ESHON
-
Publication number: 20250122197Abstract: Provided herein is a process comprising heating a composition comprising (P)-compound A or a salt thereof and a solvent to a temperature of 250° C. to 350° C. to form racemized compound A. Also provided is a process for isolating (P)-compound A from a composition comprising (P)-compound A and a tartrate, as described herein. Further provided herein, is a process for isolating a free acid of a tartrate or a hydrate thereof from a composition comprising a tartrate, (P)-compound A, and an organic solvent.Type: ApplicationFiled: December 19, 2024Publication date: April 17, 2025Applicant: AMGEN INC.Inventors: Matthew G. BEAVER, Michael T. CORBETT, Yuanqing FANG, David D. FORD, Andrew T. PARSONS, Gabrielle ST-PIERRE, Reem TELMESANI
-
Publication number: 20250121056Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.Type: ApplicationFiled: December 16, 2024Publication date: April 17, 2025Applicant: AMGEN INC.Inventors: Yuan CHENG, Chawita NETIROJJANAKUL, Jerry Ryan HOLDER, Bin WU, James R. FALSEY, Bradley J. HERBERICH, Kelvin SHAM, Leslie P. MIRANDA, Shu-Chen LU, Murielle M. VENIANT-ELLISON, Shanaka STANISLAUS, Junming YIE, Jing XU
-
Patent number: D1071156Type: GrantFiled: March 17, 2023Date of Patent: April 15, 2025Assignee: AMGEN INC.Inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Ohlenschlaeger, Gregory Thomas Nowak, Kasper Poder, Dylan Bourelle
-
Patent number: D1071160Type: GrantFiled: March 17, 2023Date of Patent: April 15, 2025Assignee: AMGEN INC.Inventors: Matias Melander, Bjarke Lykke Ludvig Svendsen, Christian Plambech, Michael Sorensen, Dylan Bourelle
-
Patent number: D1071163Type: GrantFiled: November 14, 2023Date of Patent: April 15, 2025Assignee: AMGEN INC.Inventors: Matias Melander, Bjarke Lykke Ludvig Svendsen, Christian Plambech, Dylan Bourelle, Jakob Halkjaer Pedersen, Joshua J. Dudman, Emil Gram Spork
-
Patent number: D1072240Type: GrantFiled: May 16, 2023Date of Patent: April 22, 2025Assignee: AMGEN INC.Inventors: Dylan Bourelle, Edgar Frausto, Clare O'Malley, Jakob Halkjaer Pedersen, Joshua Jay Dudman
-
Patent number: D1073061Type: GrantFiled: March 20, 2023Date of Patent: April 29, 2025Assignee: AMGEN INC.Inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Ohlenschlaeger, Gregory Thomas Nowak, Kasper Poder, Dylan Bourelle